Showing results (11-20 of 776) with videos related to
Sort By:
Pageof 78
European Journal of Clinical Investigation|February 1, 1977
Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administrationD Collen, J Schetz, F de Cock, et al.Thrombosis and Haemostasis|August 31, 1984
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosisD Collen, J M Stassen, M Blaber, et al.The Journal of Clinical Investigation|January 1, 1985
Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primatesW Flameng, F Van de Werf, J Vanhaecke, et al.Circulation|March 1, 1986
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarctionD Collen, H Bounameaux, F De Cock, et al.Circulation|November 1, 1986
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarctionF Van de Werf, J Vanhaecke, H de Geest, et al.The Journal of Pharmacology and Experimental Therapeutics|November 1, 1985
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humansM Verstraete, H Bounameaux, F de Cock, et al.Journal of the American College of Cardiology|September 1, 1992
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA)J Arnout, M Simoons, D de Bono, et al.Journal of the American College of Cardiology|December 1, 1986
Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 monthsI K Jang, J Vanhaecke, H De Geest, et al.Circulation|March 1, 1992
Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study GroupH J Rapold, D de Bono, A E Arnold, et al.Annals of Internal Medicine|April 1, 1990
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?D CollenPageof 78